Accelerating Development of Enabled Formulations for Poorly Soluble Drugs
Efficacy issues due to inadequate gastrointestinal (GI) absorption caused by insufficient aqueous solubility are encountered in up to 70% of new drugs in development. Often solubility issues are often only discovered when the drug is first administered in clinical trials. Quotient Clinical has developed an innovative approach to identify and overcome solubility challenges, which enables formulations to be designed, manufactured and clinically evaluated rapidly. Data from the early stages of the clinical evaluation can be fed back into the process, allowing formulations to be modified, manufactured and passed straight into the clinic again. This unique approach means that formulation issues can be detected, corrected and clinically validated more quickly. Click here to download/view the whitepaper.
Total Page Views: 997
